Key Points

- Tandem Diabetes Care, Inc. (TNDM) reported a quarterly loss of $0.47 per share
- The company exceeded the Zacks Consensus Estimate of a loss of $0.54 per share
- Tandem Diabetes Care announced its financial results for the second quarter of 2024
- Worldwide GAAP sales increased by 13 percent compared to the second quarter of 2023
- The company increased its sales guidance for the full year ending December 31, 2024

Tandem Diabetes Care, Inc. (TNDM) has recently reported their financial results for the second quarter of 2024, showcasing a quarterly loss of $0.47 per share, surpassing the Zacks Consensus Estimate that had predicted a loss of $0.54 per share. This performance marks a notable improvement compared to a loss of $0.30 per share reported in the same period a year ago.

The San Diego-based global insulin delivery and diabetes technology company saw a significant uptick in worldwide GAAP sales, which jumped by 13 percent to reach $221.9 million in the second quarter of 2024 compared to the same period in 2023. Additionally, non-GAAP sales saw an impressive 12 percent increase, totaling $221.8 million during this quarter.

In light of their strong performance in the second quarter, Tandem Diabetes Care, Inc. has raised its sales guidance for the full year ending December 31, 2024. The company remains optimistic about its growth prospects and is confident in its ability to deliver innovative solutions to their customers in the diabetes technology space.

The positive financial results and increased sales guidance reflect Tandem Diabetes Care's commitment to advancing insulin delivery and diabetes technology to improve the lives of those with diabetes. The company's dedication to innovation and customer satisfaction positions them for continued success in the market moving forward, with a focus on driving meaningful outcomes for patients worldwide.

With a solid foundation in place and a strong financial performance in the second quarter of 2024, Tandem Diabetes Care, Inc. is well-positioned to capitalize on the growing demand for insulin delivery and diabetes technology solutions. The company's ongoing commitment to innovation and customer-centric approach bodes well for their future growth trajectory in the dynamic healthcare landscape.

About TNDM

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

For more information:

Up/Down Rally

Price Distribution

Analyst Recommendations

Earning Price Impact Analysis

Seasonality